These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29177081)

  • 1. Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the 'ORA' registry.
    Nourisson C; Soubrier M; Mulliez A; Baillet A; Bardin T; Cantagrel A; Combe B; Dougados M; Flipo RM; Schaeverbeke T; Sibilia J; Vittecoq O; Ravaud P; Gottenberg JE; Mariette X; Tournadre A
    RMD Open; 2017; 3(2):e000515. PubMed ID: 29177081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry.
    Gottenberg JE; Ravaud P; Cantagrel A; Combe B; Flipo RM; Schaeverbeke T; Houvenagel E; Gaudin P; Loeuille D; Rist S; Dougados M; Sibilia J; Le Loët X; Marcelli C; Bardin T; Pane I; Baron G; Mariette X
    Ann Rheum Dis; 2012 Nov; 71(11):1815-9. PubMed ID: 22615458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Proportion of Subjective Component to the Disease Activity Score is Associated with Favorable Response to Abatacept in Rheumatoid Arthritis.
    Lee JS; Ahmad H; Shim SC; Bae SC; Song YW; Lee EY
    Patient; 2019 Jun; 12(3):319-326. PubMed ID: 30484084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.
    Wells G; Becker JC; Teng J; Dougados M; Schiff M; Smolen J; Aletaha D; van Riel PL
    Ann Rheum Dis; 2009 Jun; 68(6):954-60. PubMed ID: 18490431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of gender on response to rituximab in patients with rheumatoid arthritis: results from the Autoimmunity and Rituximab registry.
    Couderc M; Gottenberg JE; Mariette X; Pereira B; Bardin T; Cantagrel A; Combe B; Dougados M; Flipo RM; Le Loët X; Shaeverbeke T; Ravaud P; Soubrier M;
    Rheumatology (Oxford); 2014 Oct; 53(10):1788-93. PubMed ID: 24821852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
    Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
    Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry.
    Lahaye C; Soubrier M; Mulliez A; Bardin T; Cantagrel A; Combe B; Dougados M; Flipo RM; Le Loët X; Shaeverbeke T; Ravaud P; Mariette X; Gottenberg JE;
    Rheumatology (Oxford); 2016 May; 55(5):874-82. PubMed ID: 26822072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant methotrexate has little effect on clinical outcomes of abatacept in rheumatoid arthritis: a propensity score matching analysis.
    Takahashi N; Kojima T; Kida D; Kaneko A; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Hanabayashi M; Kato T; Funahashi K; Hayashi M; Tsuboi S; Kanayama Y; Sobue Y; Asai N; Matsumoto T; Watanabe T; Asai S; Ishiguro N
    Clin Rheumatol; 2019 Sep; 38(9):2451-2459. PubMed ID: 31102087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study.
    Alten R; Mariette X; Lorenz HM; Galeazzi M; Cantagrel A; Nüßlein HG; Chartier M; Elbez Y; Rauch C; Le Bars M
    RMD Open; 2017; 3(2):e000538. PubMed ID: 29435360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of anti-Ro/SSA antibodies in the response and retention of abatacept in patients with rheumatoid arthritis: a multicentre cohort study.
    Endo Y; Koga T; Kawashiri SY; Morimoto S; Nishino A; Okamoto M; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Hamada H; Tsuru T; Nagano S; Arinobu Y; Hidaka T; Tada Y; Kawakami A
    Scand J Rheumatol; 2021 Jan; 50(1):15-19. PubMed ID: 32880228
    [No Abstract]   [Full Text] [Related]  

  • 11. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry.
    Leffers HC; Ostergaard M; Glintborg B; Krogh NS; Foged H; Tarp U; Lorenzen T; Hansen A; Hansen MS; Jacobsen MS; Dreyer L; Hetland ML;
    Ann Rheum Dis; 2011 Jul; 70(7):1216-22. PubMed ID: 21551512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study.
    Mariette X; Alten R; Nüßlein HG; Galeazzi M; Lorenz HM; Cantagrel A; Chartier M; Poncet C; Rauch C; Le Bars M
    Joint Bone Spine; 2017 Oct; 84(5):571-576. PubMed ID: 28043761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study.
    Combe B; Dasgupta B; Louw I; Pal S; Wollenhaupt J; Zerbini CA; Beaulieu AD; Schulze-Koops H; Durez P; Yao R; Vastesaeger N; Weng HH;
    Ann Rheum Dis; 2014 Aug; 73(8):1477-86. PubMed ID: 23740226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial.
    Gottenberg JE; Brocq O; Perdriger A; Lassoued S; Berthelot JM; Wendling D; Euller-Ziegler L; Soubrier M; Richez C; Fautrel B; Constantin AL; Mariette X; Morel J; Gilson M; Cormier G; Salmon JH; Rist S; Lioté F; Marotte H; Bonnet C; Marcelli C; Sellam J; Meyer O; Solau-Gervais E; Guis S; Ziza JM; Zarnitsky C; Chary-Valckenaere I; Vittecoq O; Saraux A; Pers YM; Gayraud M; Bolla G; Claudepierre P; Ardizzone M; Dernis E; Breban MA; Fain O; Balblanc JC; Aberkane O; Vazel M; Back C; Candon S; Chatenoud L; Perrodeau E; Sibilia J; Ravaud P
    JAMA; 2016 Sep; 316(11):1172-1180. PubMed ID: 27654603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of abatacept in moderate to severe rheumatoid arthritis.
    Cortejoso-Fernández L; Romero-Jiménez MR; Pernía-López MS; Montoro-Álvarez M; Sanjurjo-Sáez M
    J Pharm Pharm Sci; 2012; 15(1):46-51. PubMed ID: 22365087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study.
    Kim SK; Choe JY; Park SH; Lee H
    Clin Rheumatol; 2016 May; 35(5):1129-36. PubMed ID: 26932795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study.
    Wiland P; Jeka S; Dokoupilová E; Brandt-Jürgens J; Miranda Limón JM; Cantalejo Moreira M; Cabello RV; Jauch-Lembach J; Thakur A; Haliduola H; Brueckmann I; Gaylis NB
    BioDrugs; 2020 Dec; 34(6):809-823. PubMed ID: 33119861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting.
    Vázquez I; Graell E; Gratacós J; Cañete JD; Viñas O; Ercilla MG; Gómez A; Hernández MV; Rodríguez-Cros JR; Larrosa M; Sanmartí R
    Clin Exp Rheumatol; 2007; 25(2):231-8. PubMed ID: 17543147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.